Research PaperResearchia:202602.16026[Medicine > Open Science]
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Chloe Orkin
Abstract
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Source: OpenAlex - The Lancet (Citations: 2) PDF: N/A Original Link: https://doi.org/https://doi.org/10.1016/s0140-6736(25)01945-2
Submission:2/16/2026
Comments:0 comments
Subjects:Open Science; Medicine
Cite as:
Researchia:202602.16026https://www.researchia.net/explorer/98e81132-7844-4e9f-b1ff-63bb373ee166
Original Source:
Was this helpful?